Marker Therapeutics Inc. (MRKR) is trading at $3.15 in pre-market trading Tuesday, an increase of 17.10% from the previous closing price of $2.69, following news related to its planned phase II trial of MultiTAA T cell therapy in patients with post-transplant acute myeloid leukemia.
from RTT - Before the Bell https://ift.tt/31K4Cj8
via IFTTT
No comments:
Post a Comment